Category Archives: Public Policy

Latest From Public Policy

New Report Suggests RDP Does Not Increase Healthcare Expenditures

health care, medicine

A new paper by the Geneva Network suggests that increasing the period of regulatory data protection (RDP) for biologic medicines would not increase expenditures for medicines. As countries navigate the final negotiations in the Trans-Pacific Partnership, the U.S. and Japan have advocated for increased regulatory data protection for biologic medicines by other TPP countries. In the U.S. biologics enjoy 12 years of data exclusivity; the only TPP countries, aside from the U.S, offering more than Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , ,

225th Anniversary of First U.S. Patent


225 years ago last Friday the first U.S. patent was issued to Samuel Hopkins for an improved process for creating potash, America’s first industrial chemical compound. America’s Founding Fathers recognized Intellectual property as a fundamental right, so much so they enshrined it into our Constitution. The systems for issuing patents have changed over the years, but Congress retains the authority to regulate and change matters of patent law. Unfortunately, not all changes to patent law Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

Seventy Nine House Members Express Concern with H.R. 9

Vote No on HR 9

House leaders made the decision earlier this month to remove patent reform legislation from the schedule for the remaining days before the August recess. While a vote is expected to occur sometime in September, House Majority Leader Kevin McCarthy made the decision to review and address many of the concerns that have been voiced by an array of industries that require the value of dependable and enforceable patents. In the words of Representative McCarthy, “I Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , ,

CNBC Commentary: Hedge funds, ‘reverse trolls’ crushing biopharma innovation

Vote No on HR 9

Patents are the lifeblood of medical innovation. They are the cornerstone that enables companies to perform the long and costly research and development for cures and therapies to combat devastating diseases such as cancer, HIV and Alzheimer’s. Unfortunately, the system that helps protect these innovations is being abused by outside interests. BIO and others have called upon Congress to fix these problems as part of a greater patent reform debate. Today one more voice joined Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , ,

BIO Letter of Support for 21st Century Cures Legislation

21st Century Cures Act

Today, BIO sent a letter to Reps. Boehner and Pelosi in support of the 21st Century Cures Act. In the letter, we applaud Chairman Upton, Ranking Member Pallone and Congresswoman DeGette’s efforts on H.R. 6., which takes important steps toward placing patients at the center of the drug development process. We also expressed support for precision medicine through genomics and regulatory science to help better understand the molecular basis of disease and develop precision therapies tailored to each Read More >

Business and Investments, Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , ,